UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________________
FORM 6-K
________________________________________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2023
Commission File Number: 001-39152
________________________________________________________
FSD PHARMA INC. |
(Registrant) |
________________________________________________________
199 Bay St., Suite 4000
Toronto, Ontario M5L 1A9 Canada
(Address of Principal Executive Offices)
________________________________________________________
Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
FSD PHARMA INC. |
| ||
(Registrant) |
| ||
| |||
Date November 6, 2023 | By | /s/ Nathan Coyle |
|
Nathan Coyle |
| ||
Chief Financial Officer |
|
2 |
EXHIBIT INDEX
Exhibit |
| Description of Exhibit |
| ||
|
|
|
| ||
|
|
|
| News Release dated October 5, 2023 – FSD Pharma and Celly NU Enter into Arrangement Agreement |
3 |